E85.89 ICD-10-CM Code: Other amyloidosis
E85.89 maps to CMS-HCC V28 50 (RAF 0.648). Documentation must support MEAT. MEAT criteria · RAF calculator · HCC coding software
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Endocrine, nutritional and metabolic diseases (E00-E89) / Metabolic disorders (E70-E88)
E85.89
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceOther amyloidosis
Accumulation of abnormal amyloid proteins in the body from causes other than light chain or transthyretin types, such as secondary amyloidosis or other rare forms.
Buddy Insight
Other amyloidosis captures specified forms of amyloidosis not classified elsewhere, including dialysis-related amyloidosis (beta-2-microglobulin), localized forms with specific amyloid types, and rare amyloid subtypes.
CMS-HCC V28
MappedHCC 50
RAF 0.648
CMS-HCC V24
MappedHCC 23
RAF 0.194
ACA/HHS
MappedHCC 29
Varies by metal level
ESRD/PACE
MappedHCC 23
RAF 0.036
RXHCC
N/A—
Not mapped
Code Book Path
Inclusion Terms
OfficialICD-10-CM does not list inclusion terms for E85.89 in this effective period.
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for E85.89 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for E85.89 in this effective period.
Excludes 1
OfficialICD-10-CM does not list Excludes 1 notes for E85.89 in this effective period.
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for E85.89 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for E85.89 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for E85.89 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is E85.89 an HCC code?
Yes. E85.89 (Other amyloidosis) maps to Amyloidosis, Porphyria, and Other Specified Metabolic Disorders under the CMS-HCC V28 risk adjustment model (and Other Significant Endocrine and Metabolic Disorders under V24), with a community non-dual aged RAF of 0.648. It is billable for payment year 2026.
Coder answer: E85.89 is billable and maps to V28 HCC 50, Amyloidosis, Porphyria, and Other Specified Metabolic Disorders. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.
- Code
- E85.89
- Description
- Other amyloidosis
- HCC (V28)
- HCC 50 — Amyloidosis, Porphyria, and Other Specified Metabolic Disorders
- RAF
- 0.648
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
Each model's RAF is its CMS base weight for that model's standard population, so weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
Work E85.89 in the Code Book — tabular path, V28 RAF, and MEAT checklist →
MEAT Criteria for E85.89
For E85.89 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed E85.89 during that encounter, not just copy-forwarded from a problem list.
Coder workflow notes
Get the V28 RAF + MEAT cheat sheet
One printable page: confirm a code's V28 HCC status, its RAF weight, and the MEAT your note needs to make it stick. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
E85.89 is the ICD-10-CM diagnosis code for other amyloidosis. Accumulation of abnormal amyloid proteins in the body from causes other than light chain or transthyretin types, such as secondary amyloidosis or other rare forms. E85.89 sits in the ICD-10-CM chapter for endocrine, nutritional and metabolic diseases (e00-e89), within the section covering metabolic disorders (e70-e88).
Under the CMS-HCC V28 risk adjustment model, E85.89 maps to Amyloidosis, Porphyria, and Other Specified Metabolic Disorders (HCC 50) with a community, non-dual, aged base RAF weight of 0.648. Under the older CMS-HCC V24 model, E85.89 maps to Other Significant Endocrine and Metabolic Disorders (HCC 23) with a community, non-dual, aged base RAF weight of 0.194. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Use this code only when the specific type of amyloidosis is documented but does not fit E85.81 or E85.82. Because E85.89 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for E85.89 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
Clinical Significance
Other amyloidosis captures specified forms of amyloidosis not classified elsewhere, including dialysis-related amyloidosis (beta-2-microglobulin), localized forms with specific amyloid types, and rare amyloid subtypes. Proper classification ensures accurate disease tracking and risk adjustment.
Documentation Requirements
- ✓Confirmed amyloidosis diagnosis by tissue biopsy with amyloid typing
- ✓Specific amyloid type identified (beta-2-microglobulin, fibrinogen, apolipoprotein, etc.)
- ✓Reason the amyloidosis does not fit other specific codes (E85.0-E85.82)
- ✓Affected organ systems and functional impact
- ✓Treatment plan and monitoring schedule
Commonly Confused Codes
- •E85.81: Light chain (AL) amyloidosis: specific code for light chain deposits from plasma cell disease
- •E85.82: Wild-type transthyretin-related (ATTR) amyloidosis: specific code for age-related ATTR
- •E85.3: Secondary systemic amyloidosis: reactive AA type from chronic inflammation
- •E85.9: Amyloidosis, unspecified: use only when the type is completely unknown